{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'changed.', '4.4 Withdrawal Criteria and Procedures (Other sections affected by this change: 7.1.7; Section 7.5)', 'In accordance with the Declaration of Helsinki', 'In accordance with the Declaration', 'Text to identify', \"(in accordance with the applicable country's\", 'of Helsinki (in accordance with the', 'QTc changes', 'acceptance), each patient is free to withdraw', \"applicable country's acceptance),\", 'that will require', 'from the study at any time. The investigator also', 'each patient is free to withdraw', 'IMP', 'has the right to withdraw a patient from the', 'from the study at any time. The', 'suspension was', 'study in the event of intercurrent illness,', 'investigator also has the right to', 'added.', 'adverse events, pregnancy (see Section 7.3), or', 'withdraw a patient from the study in', 'other reasons concerning the health or', 'the event of intercurrent illness,', 'well-being of the patient, or in the event of lack', 'adverse events, pregnancy (see', 'of cooperation. If a post-baseline QTcF value', 'Section 7.3), or other reasons', '>500 msec or change from baseline >60 msec is', 'concerning the health or well-being', 'found, the investigator should repeat the ECG', 'of the patient, or in the event of lack', 'assessment twice and compare the average of', 'of cooperation. If a post-baseline', 'the 2 pre-treatment QTcF values (baseline and', 'QTcF value >500 msec or change', 'screening) to the average of the 3 post-baseline', 'from baseline >60 msec is found,', 'QTcF values. The IMP must be stopped for any', 'the investigator should repeat the', 'confirmed post-baseline QTcF value >500 msec', 'ECG assessment twice and compare', 'or increase from baseline >60 msec.', 'the average of the 2 pre-treatment', 'QTcF values (baseline and', 'screening) to the average of the 3', 'post-baseline QTcF values. The IMP', 'must be stopped for any confirmed', 'post-baseline QTcF value >500', 'msec or increase from baseline >60', 'msec.', '5.1. Drugs Administered During the Study', 'Weight category Daily dose', 'Daily dose (mg) at', 'The table was', '(mg) at the start of visit/week', 'the start of', 'updated with', 'visit/week', 'weight details', 'Study', '20 to <30', '30 to', '>40 kg', 'and', 'week', 'kg', '<40 kg', '(>88 lbs)', 'Stud', '20 to', '30 to', '>40', 'clarifications', '(44 to', '66 to', 'y', '<30', '<40', 'kg', 'regarding how', '<66 lbs)', '<88 lbs)', 'week', 'kg', 'kg', '(88', 'study weeks are', 'a', 'Week 1', '(66', 'defined with', '6 mg', '6 mg', '6 mg', '(44 to', 'lbs)', '(Days 1', '<66', 'to', 'the occurring at', 'Baseline', 'and 2)', 'lbs)', '<88 l', 'the beginning', 'bs)', 'of the week.', '12 mgb', 'Week Z 1', '12 mg', '12 mg', '18 mg', 'Week 3 2', '18 mg', '18 mg', '24 mg', 'Week 43', '18 mgc', '24 mgc', '30 mg', '125']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'Week 54', '24 mgc', '30 mgc', '36 mgc', 'Basel', '6 mg', '6 mg', '6 mg', 'ine', 'Week 6 5', '24 mgc', '36 mgc', '42 mgc', '(Days', '1 and', 'Week 7 6', '30 mgc', '42 mgc', '48 mgc', '2)', '12', 'mgb', 'Wee', '12', '12', '18', 'k 1', 'mg', 'mg', 'mg', 'Wee', '18', '18', '24', 'k 2', 'mg', 'mg', 'mg', 'Wee', '18', '24', '30', 'k 3', 'mgc', 'mgc', 'mg', 'Wee', '24', '30', '36', 'k 4', 'mgc', 'mgc', 'mgc', 'Wee', '24', '36', '42', 'k 5', 'mgc', 'mgc', 'mgc', 'Wee', '30', '42', '48', 'k 6', 'mgc', 'mgc', 'mgc', '7.5. Clinical Laboratory Tests', 'The clinical significance of the lab values will', 'The clinical significance of the lab', 'This sentence', 'be evaluated by the criteria described in the', 'values will be evaluated by the', 'included to', 'study lab manual and by the judgment of the', 'criteria described in the study lab', 'provide further', 'investigator.', 'manual and by the judgment of the', 'guidance', 'investigator.', 'regarding', 'clinical', 'significance of', 'laboratory', 'values and', 'investigator', 'judgement.', '7.7. Electrocardiography', 'A 12-lead ECG will be conducted at the time', 'A 12-lead ECG will be conducted at', 'Twelve-lead', 'points detailed in Table 1. All ECGs will be', 'the time points detailed in Table 1.', 'ECG', 'performed after at least 5 minutes rest in a', 'All ECGs will be performed after at', 'interpretation', 'supine or semi-supine position. A qualified', 'least 5 minutes rest in a supine or', 'details were', 'physician at a central diagnostic center will be', 'semi-supine position. A qualified', 'updated.', 'interpreting the ECG.', 'physician at a central diagnostic', 'All ECG results outside of the reference ranges', 'center will be interpreting the ECG.', 'will be judged by the investigator as belonging', 'All ECG results outside of the', 'to one of the following categories:', 'reference ranges will be judged by', '126']\n\n###\n\n", "completion": "END"}